Selective HDAC6 inhibitors, including Tubastatin A, CAY10603, ACY-1215, and A452, have been shown to inhibit activation of EGFR and p53 pathways, reduce MGMT expression, and sensitize GBM cells to TMZ [85, 251]. Here, EGFR is linked to glioblastoma.